Kısa Rapor
BibTex RIS Kaynak Göster

Single center experience in patients with a diagnosis of nodular lymphocyte predominant Hodgkin lymphoma

Yıl 2021, Cilt: 3 Sayı: Supplement 1, 40 - 41, 07.03.2021
https://doi.org/10.46310/tjim.877049

Öz

Nodular lymphocyte predominant Hodgkin lymphoma is an infrequent disease. It is associated with a favorable prognosis. The most important problems with the management of the disease are relapses, transformation to non-Hodgkin lymphoma, and treatment-related toxicities. In early stages of disease, watchful waiting, surgery, radiotherapy, and single-agent rituximab are the treatment options. Chemo-immunotherapy may be preferred in early disease with high tumor and symptom burden. In advanced disease, chemo-immunotherapy with or without radiotherapy is used. Good responses can be achieved in relapsed disease. The risk of transformation is high. It is reasonable to obtain re-biopsies at relapses. Transformed disease and the primary disease have been shown to be clonally-related in most cases. Prognosis of transformed disease which is treated with salvage chemo-immunotherapy followed by autologous stem cell transplantation is similar to that of de novo diffuse large B-cell lymphoma. All of the data regarding the treatment come from retrospective data.

Kaynakça

  • Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019 Jan;184(1):17-29. doi: 10.1111/bjh.15616. Epub 2018 Nov 28. PMID: 30485408.
  • Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020 Jan;52(1):142-153. doi: 10.1016/j.pathol.2019.10.003. Epub 2019 Nov 28. PMID: 31785822.
  • Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. PMID: 30770396; PMCID: PMC7022227.
Yıl 2021, Cilt: 3 Sayı: Supplement 1, 40 - 41, 07.03.2021
https://doi.org/10.46310/tjim.877049

Öz

Kaynakça

  • Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019 Jan;184(1):17-29. doi: 10.1111/bjh.15616. Epub 2018 Nov 28. PMID: 30485408.
  • Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020 Jan;52(1):142-153. doi: 10.1016/j.pathol.2019.10.003. Epub 2019 Nov 28. PMID: 31785822.
  • Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. PMID: 30770396; PMCID: PMC7022227.
Toplam 3 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular İç Hastalıkları
Bölüm Short Report
Yazarlar

Ömer Candar 0000-0001-7602-6926

Fahir Özkalemkaş 0000-0001-9710-134X

Vildan Ozkocaman 0000-0003-0014-7398

Tuba Ersal Bu kişi benim 0000-0001-5419-3221

İbrahim Ethem Pınar 0000-0001-9907-1498

Cumali Yalçın Bu kişi benim 0000-0002-5129-2977

Bedrettin Orhan 0000-0003-3970-2344

Yayımlanma Tarihi 7 Mart 2021
Gönderilme Tarihi 18 Şubat 2021
Kabul Tarihi 5 Mart 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 3 Sayı: Supplement 1

Kaynak Göster

EndNote Candar Ö, Özkalemkaş F, Ozkocaman V, Ersal T, Pınar İE, Yalçın C, Orhan B (01 Mart 2021) Single center experience in patients with a diagnosis of nodular lymphocyte predominant Hodgkin lymphoma. Turkish Journal of Internal Medicine 3 Supplement 1 40–41.

e-ISSN: 2687-4245 

Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png
2023 -TJIM.org